Literature DB >> 15646253

Pharmacokinetics and pharmacodynamics of olprinone after cardiac surgery.

Masanobu Mori1, Shinichi Nishi, Akira Asada.   

Abstract

BACKGROUND: Phosphodiesterase type III inhibitors are often delivered by continuous intravenous infusion without initial loading to prevent hypotension, i.e., by "slow induction". We evaluated the pharmacokinetics (PK) and pharmacodynamics (PD) of olprinone slow induction after open-heart surgery.
METHODS: Olprinone was infused at a rate of 0.2 microg x kg(-1) x min(-1) in seven patients post operatively after elective cardiac surgery. Olprinone plasma concentration was determined by HPLC. PK parameters were calculated from concentrations at 90 and 180 minutes after start of infusion. PD data were analyzed by collected E(max) model using SAAMII PC programs.
RESULTS: Systemic vascular resistance index initially decreased about 20 ng/mL and then cardiac index increased. Initially, a vasodilating effect occurs and then inotropic effect follows. Systemic hypotension may induced by the different EC50 between inotropic and vasodilating action. Moreover, much vasodilating effect will be observed with olprinone than with milrinone, based on our previous data.
CONCLUSIONS: Olprinone slow induction is useful and safe for critically ill patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15646253

Source DB:  PubMed          Journal:  Osaka City Med J        ISSN: 0030-6096


  4 in total

1.  Differential vasodilation response to olprinone in rabbit renal and common carotid arteries.

Authors:  Toshiyuki Minonishi; Koji Ogawa; Yasuyuki Tokinaga; Takaaki Negoro; Yoshiki Kimoto; Yoshio Hatano
Journal:  J Anesth       Date:  2010-02       Impact factor: 2.078

2.  Population pharmacokinetics of olprinone in patients undergoing cardiac surgery with cardiopulmonary bypass.

Authors:  Tsunehisa Tsubokawa; Syuichi Ishizuka; Kyoko Fukumoto; Kazuyuki Ueno; Ken Yamamoto
Journal:  J Anesth       Date:  2012-10-23       Impact factor: 2.078

3.  Anesthetic management for ascending aorta replacement in a patient who refused autologous transfusion for religious reasons.

Authors:  Shinju Obara; Masayuki Nakagawa; Shinichiro Takahashi; Masahiko Akatu; Tsuyoshi Isosu; Masahiro Murakawa
Journal:  J Anesth       Date:  2009-08-14       Impact factor: 2.078

4.  The effect of hemodilution by cardiopulmonary bypass on protein binding of olprinone.

Authors:  Tsunehisa Tsubokawa; Syuichi Ishizuka; Kyoko Fukumoto; Kazuyuki Ueno; Ken Yamamoto
Journal:  J Anesth       Date:  2012-11-23       Impact factor: 2.078

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.